Perry Shen, MD
Perry Shen, MD is a surgical oncologist at Wake Forest Baptist Medical Center and Comprehensive Cancer Center in Winston-Salem, North Carolina. He is a Professor of Surgery and surgeon who specializes in oncological problems involving the liver, the pancreas, the bowel duct, and gallbladder, as well as gastrointestinal malignancies involving peritoneal surface tumors like malignant peritoneal mesothelioma.[1] He is one of the few surgeons in the country who is skilled in the use of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery. This complex surgery has proven to be one of the most innovative and effective treatments for this rare and challenging diagnosis.
Education and Career
Dr. Shen earned his medical degree at Keck School of Medicine of the University of Southern California. He then attended Johns Hopkins University School of Medicine for his internship and the University of Southern California Los Angeles County and USC Medical Center for his residency in General Surgery. Dr. Shen then completed a fellowship in Surgical Oncology at the John Wayne Cancer Institute. He is board-certified in Surgery.[1]
Professional Memberships
Dr. Shen is an active member of numerous professional and medical societies, including:[1]
- American Hepato-Pancreato-Biliary Association
- North Carolina Surgical Association
- Association of Academic Surgery
- Society of Surgical Oncology
- Forsyth-Davie-Stokes Medical Society
- American Association of Cancer Research
- North Carolina Medical Association
- Southern Surgical Society
- American College of Surgeons
- American Society of Clinical Oncology
- American Medical Association
- Society of Graduate Surgeons
- Southeastern Surgical Congress
- Society for Surgery of Alimentary Tract
Research
Dr. Shen is currently studying the use of a hepatic pump to deliver chemotherapy directly to the liver. He is testing a technique called microwave ablation for use in patients with inoperable liver tumors. He is also involved in several breast cancer clinical trials and is the principal investigator for a study on predicting the risk of melanoma spreading to nearby organs.[2]
He is currently involved in a clinical trial titled Learning More About the Benefits of Chemotherapy Before and After Surgery for Gallbladder Cancer.
Recent publications include:[1]
- Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. J. Am. Coll. Surg. 2014 Apr; 218(4):573-85.
- Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, Stewart JH, Mirzazadeh M. Ann. Surg. Oncol. 2014 Mar; 21(3):868-74.
- Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Ann. Surg. Oncol. 2014 May; 21(5):1474-9.
- Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Votanopoulos KI, Swords DS, Swett KR, Randle RW, Shen P, Stewart JH, Levine EA. Ann. Surg. Oncol. 2013 Nov; 20(12):3899-904.
- Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Ann. Surg. Oncol. 2014 May; 21(5):1501-5.
